Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
暂无分享,去创建一个
Catherine J. Wu | J. Wagner | Wandi Zhang | L. Krishnamurti | K. Baker | K. Baker | M. Biernacki | S. Kharbanda | Catherine J. Wu | J. E. Wagner
[1] E. Thiel,et al. Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.
[2] K. Sullivan,et al. Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] A. Chuansumrit,et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients , 2007, American journal of hematology.
[4] M. Gladwin,et al. Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis , 2007, British journal of haematology.
[5] A. Fischer,et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. , 2007, Blood.
[6] M. Walters. Cord blood transplantation for sickle cell anemia: Bust or boom? , 2007, Pediatric transplantation.
[7] J. Klein,et al. Matched‐related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research , 2007, British journal of haematology.
[8] C. Garone,et al. No Kinetic Interaction Between Levetiracetam and Cyclosporine: A Case Report , 2007, Journal of child neurology.
[9] L. Krishnamurti. Hematopoietic cell transplantation for sickle cell disease: state of the art , 2007, Expert opinion on biological therapy.
[10] J. Kurtzberg,et al. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. , 2006, Journal of pediatric hematology/oncology.
[11] R. Krance,et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath) , 2005, Bone Marrow Transplantation.
[12] J. Kutok,et al. Evidence for ineffective erythropoiesis in severe sickle cell disease. , 2005, Blood.
[13] Cage S. Johnson,et al. Outcome of Sickle Cell Anemia: A 4-Decade Observational Study of 1056 Patients , 2005, Medicine.
[14] D. Bloch,et al. Protective conditioning for acute graft-versus-host disease. , 2005, The New England journal of medicine.
[15] Allen R. Chen,et al. Bone marrow transplantation for sickle cell anemia: Progress and prospects , 2005, Pediatric blood & cancer.
[16] R. Storb,et al. Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. , 2005, Blood reviews.
[17] R. Storb,et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning , 2005, Bone Marrow Transplantation.
[18] J. Dipersio,et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders , 2005, Bone Marrow Transplantation.
[19] J. Liesveld,et al. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin , 2005, Bone Marrow Transplantation.
[20] M. Walters. Stem cell therapy for sickle cell disease: transplantation and gene therapy. , 2005, Hematology. American Society of Hematology. Education Program.
[21] S. Pakakasama,et al. Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 lucarelli severe thalassemia patient , 2004, Bone Marrow Transplantation.
[22] A. Svejgaard,et al. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] E. Manci,et al. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. , 2003, Blood.
[24] P. Thall,et al. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] J. Kutok,et al. Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. , 2003, Experimental hematology.
[26] Allen R. Chen,et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] M. Maris,et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.
[28] S. Strober,et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[29] R. Storb,et al. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. , 2003, Hematology. American Society of Hematology. Education Program.
[30] M. Steinberg. Hydroxyurea Treatment for Sickle Cell Disease , 2002, TheScientificWorldJournal.
[31] G. Ledderose,et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. , 2002, Experimental hematology.
[32] K. Sullivan,et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] J. Wagner,et al. Bone marrow transplantation without myeloablation for sickle cell disease. , 2001, The New England journal of medicine.
[34] J. Sosman,et al. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease , 2000, Bone Marrow Transplantation.
[35] C. Pegelow,et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. , 2000, Blood.
[36] E. Vichinsky,et al. Major changes in sickle cell disease. , 2000, Advances in pediatrics.
[37] N. Young,et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. , 1999, Blood.
[38] J. Scott,et al. Bone marrow transplantation for sickle cell disease. , 1996, The New England journal of medicine.
[39] J. Scott,et al. Barriers to bone marrow transplantation for sickle cell anemia. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[40] M. Andreani,et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. , 1996, Blood.
[41] H. Deeg,et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. , 1996, Blood.
[42] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[43] M. Abboud,et al. Bone marrow transplantation for sickle cell anemia. , 1994, The American journal of pediatric hematology/oncology.
[44] G. Lucarelli,et al. Bone marrow transplantation in sickle-cell anemia in Pesaro. , 1993, Bone marrow transplantation.
[45] E. Sariban,et al. Bone marrow transplantation for severe sickle cell anaemia , 1992, British journal of haematology.
[46] D. Engelhard,et al. The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders. , 1989, Transplantation proceedings.